<DOC>
	<DOC>NCT00568841</DOC>
	<brief_summary>This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer (NSCLC) treated with Erlotinib.</brief_summary>
	<brief_title>Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Written informed consent â‰¥ 18 years of age Untreated nonsmallcell lung cancer stage IIIB/IV Life expectancy &gt; 3 months Performance status ECOG 02 Concurrent systemic immune therapy, chemotherapy or therapy with any anticancer drug not indicated in the study protocol Any investigational agent(s) within 4 weeks prior to study entry Previous administration of any EGFRtargeted therapy (antibodies, small molecules and others) Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>advanced Non-Small-Cell Lung Cancer</keyword>
	<keyword>erlotinib</keyword>
	<keyword>FDG-PET</keyword>
	<keyword>FLT-PET</keyword>
</DOC>